5154 Background: Targeting of mTOR and vascular endothelial growth factor (VEGF) alone
or with chemotherapy has been reported for CRPC. We report a dose finding study …

Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of
orteronel (TAK-700) plus prednisone Page 1 Results from a phase 3, randomized, double-blind …

OBJECTIVE: To investigate the activity and toxicity of metronomic chemotherapy with low-
dose oral cyclophosphamide (CTX) and methotrexate (MTX) in patients with metastatic …

e16031 Background: Abiraterone acetate (AA) has demonstrated survival benefit in the pre-
chemotherapy setting for patients (pts) with mCRPC, now with widespread clinical use …

Most men with metastatic prostate cancer respond to various types of androgen ablation but
progress to castration-resistant disease. The TAX 327 and Southwest Oncology Group …

Background Guidelines define docetaxel as a first‐line therapeutic option for metastatic
castration‐resistant prostate cancer (mCRPC). However, the role of docetaxel in non …

Standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) is
docetaxel plus prednisone; however, patients will usually experience disease progression …

BACKGROUND: Many agents have shown survival advantage in metastatic castrate-
resistant prostate cancer (mCRPC). Despite this improvement, survival is poor, especially in …

Background: The mammalian target of rapamycin (mTOR) pathway is deregulated in
castration-resistant prostate cancer (CRPC). We investigated the efficacy and toxicity of …

Background: Treatment with docetaxel in combination with prednisone is the standard first-
line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). For …